Hims & Hers Lost 22% in a Week. Needham Still Sees 54% Upside From Here
Hims & Hers Health (HIMS) fell 22% in a week after cutting its 2026 profit outlook for the third time, despite a 49% revenue growth in Q3. Gross margin dropped to 57% from 74%, and subscribers decreased. Needham maintains a Buy rating with a $32 target, seeing 54% upside.
How this was made
The 30-second read
Why it matters
The guidance reduction is a fresh, material development that likely drives short‑term price weakness.
Market read
The news directly impacts HIMS stock with a likely negative price move; peers may see secondary sentiment effects.
What to watch
Potential upside from Eli Lilly's direct sales channel on Hims could offset margin compression if subscriber churn slows.
Background
Hims & Hers Health reported a 49% revenue increase but a sharp margin decline and a third profit outlook cut for 2026, while subscriber numbers fell.
Ticker impact
Hims & Hers cut its 2026 profit outlook for the third time, triggering a 16.6% share drop and a 22% weekly loss.
likely further downside as investors price in reduced profitability
The third outlook reduction and accompanying revenue margin decline are fresh, material facts that typically drive sell pressure.
Market effects
Weight‑loss drug segment faces margin pressure, may affect peers in telehealth and pharma collaborations.
U.S. telehealth stocks could see modest pullback as guidance cuts raise concerns.
Limited to companies tied to weight‑loss drug distribution and telehealth platforms.
Counterpoint
If Zepbound sales accelerate and subscriber base stabilizes, the stock could rebound despite the guidance cut.
Key entities
- companyHims & Hers Health
Telehealth firm experiencing profit outlook cuts and subscriber decline.
- companyEli Lilly
Partner drug maker whose products are sold through Hims.
